Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925687 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04925687 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 4 participants.
The verdict
NCT04925687, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.
Interventions
- BIOLOGICAL Intravitreal autologous CD34+ cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925687
The ClinicalTrials.gov registry entry for NCT04925687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal autologous CD34+ cells is the first listed.
NCT04925687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04925687 about?
NCT04925687 is a clinical study titled "Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa". In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection ...
What is the current status of trial NCT04925687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-06-01. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT04925687?
The interventions under investigation include: Intravitreal autologous CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04925687?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.